ANI launches CDMO arm after WellSpring integration

31-Oct-2019 - Last updated on 11-Nov-2019 at 09:56 GMT

(Image: Getty/serhat özşen)

ANI Pharmaceuticals expands into the CDMO market and introduced its services for late-stage developers at CPhI last week.

One year after acquiring the contract manufacturing services provider, WellSpring Pharma, for $18m (€16.11m), ANI Pharmaceutical announced the launch of its own contract development and manufacturing organization (CDMO) brand, known as ANI Global Source.

According to ANI, the launch of the brand demonstrates the progress that the company has made since the WellSpring acquisition. The newly-established business was presented at the CPhI Worldwide event last week in Frankfurt, Germany.

According to ANI, the brand will be supporting late-stage development and commercial manufacture for small molecule drug products in several non-sterile dosage formulations, including tablets and capsules, liquid solutions, suspensions, topical liquids, creams and gels, potent compounds, and controlled substances.

A spokesperson for the company told us that interest has already been shown from developers in collaborating with the brand, and that it is currently working with them to plan and establish their programs.

Asked about the demands that the company aims to answer in the competitive CDMO market, the spokesperson replied that the focus is currently on “helping small- to medium-sized pharmaceutical companies that are in late-stage product development commercialize their new therapies.”

“We are also well positioned to support animal health pharmaceutical companies and we have the experience to work with teams to quickly launch their Rx generic drugs,” the spokesperson added.

The CDMO will employ 300 people working in 270,000-square-feet of manufacturing and packaging facilities across multiple sites, headquartered along with the parent company in Minnesota, US.